메뉴 건너뛰기




Volumn 29, Issue 3, 2008, Pages 264-266

KIT protein expression in uterine sarcomas: An immunohistochemical study and review of the literature

Author keywords

Imatinib mesylate; KIT; Uterine sarcoma

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

EID: 44349166828     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (6)

References (23)
  • 1
    • 0002817386 scopus 로고
    • Classifying, staging, and treating uterine sarcomas
    • Forney J.P., Buschbaum H.J.: "Classifying, staging, and treating uterine sarcomas". Contemp. Obstet. Gynecol., 1981, 18, 47.
    • (1981) Contemp. Obstet. Gynecol , vol.18 , pp. 47
    • Forney, J.P.1    Buschbaum, H.J.2
  • 2
    • 0030744043 scopus 로고    scopus 로고
    • Uterine sarcomas in Norway 1956-1992: Incidence, survival and mortality
    • Nordal R.R., Thoreson S.O.: "Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality". Eur. J. Cancer, 1997, 33, 907.
    • (1997) Eur. J. Cancer , vol.33 , pp. 907
    • Nordal, R.R.1    Thoreson, S.O.2
  • 3
    • 18144375567 scopus 로고    scopus 로고
    • Systemic therapy for advanced uterine sarcoma: A systematic review of the literature
    • Kanjeekal S., Chambers A., Fung M.F., Verma S.: "Systemic therapy for advanced uterine sarcoma: a systematic review of the literature". Gynecol. Oncol., 2005, 97, 624.
    • (2005) Gynecol. Oncol , vol.97 , pp. 624
    • Kanjeekal, S.1    Chambers, A.2    Fung, M.F.3    Verma, S.4
  • 5
    • 15544374557 scopus 로고    scopus 로고
    • A comparison between different postoperative treatment modalities of uterine carcinosarcoma
    • Menczer J., Levy T., Piura B. et al.: "A comparison between different postoperative treatment modalities of uterine carcinosarcoma". Gynecol. Oncol., 2005, 97, 166.
    • (2005) Gynecol. Oncol , vol.97 , pp. 166
    • Menczer, J.1    Levy, T.2    Piura, B.3
  • 6
    • 0035810148 scopus 로고    scopus 로고
    • Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
    • Joensuu H., Roberts P.J., Sarlomo-Rikala M. et al.: "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor". N. Engl. J. Med., 2001, 344, 1052.
    • (2001) N. Engl. J. Med , vol.344 , pp. 1052
    • Joensuu, H.1    Roberts, P.J.2    Sarlomo-Rikala, M.3
  • 7
    • 0035960428 scopus 로고    scopus 로고
    • Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study
    • van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S. et al.: "Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study". Lancet 2001, 358, 1421.
    • (2001) Lancet , vol.358 , pp. 1421
    • van Oosterom, A.T.1    Judson, I.2    Verweij, J.3    Stroobants, S.4    Donato di Paola, E.5    Dimitrijevic, S.6
  • 9
    • 20044378513 scopus 로고    scopus 로고
    • Treatment of gastrointestinal stromal tumors with imatinib mesylate: A major breakthrough in the understanding of tumor-specific molecular characteristics
    • de Mestier P., des Guetz G.: "Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics". World J. Surg., 2005, 29, 357.
    • (2005) World J. Surg , vol.29 , pp. 357
    • de Mestier, P.1    des Guetz, G.2
  • 10
    • 0023340925 scopus 로고
    • Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ERICA) in breast cancer tissue
    • Remmele W., Stegner H.E.: "Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ERICA) in breast cancer tissue". Pathologe, 1987, 8, 138.
    • (1987) Pathologe , vol.8 , pp. 138
    • Remmele, W.1    Stegner, H.E.2
  • 11
    • 0037186924 scopus 로고    scopus 로고
    • Imatinib mesylate - a new oral targeted therapy
    • Savage D.G., Antman K.H.: "Imatinib mesylate - a new oral targeted therapy". N. Engl. J. Med., 2002, 2346, 683.
    • (2002) N. Engl. J. Med , vol.2346 , pp. 683
    • Savage, D.G.1    Antman, K.H.2
  • 12
    • 15644363454 scopus 로고    scopus 로고
    • Gain of function mutations of c-kit in human gastrointestinal stromal tumors
    • Hirota S., Isozaki K., Moriyama Y. et al.: "Gain of function mutations of c-kit in human gastrointestinal stromal tumors". Science, 1998, 279, 577.
    • (1998) Science , vol.279 , pp. 577
    • Hirota, S.1    Isozaki, K.2    Moriyama, Y.3
  • 13
    • 0141869087 scopus 로고    scopus 로고
    • rd, Seidman J.D., Krivak T.C. et al.: Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol. Oncol., 2003, 91, 3.
    • rd, Seidman J.D., Krivak T.C. et al.: "Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus". Gynecol. Oncol., 2003, 91, 3.
  • 14
    • 0037378396 scopus 로고    scopus 로고
    • Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary
    • Klein W.M., Kurman R.J.: "Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary". Int. J. Gynecol. Pathol., 2003, 22, 181.
    • (2003) Int. J. Gynecol. Pathol , vol.22 , pp. 181
    • Klein, W.M.1    Kurman, R.J.2
  • 16
    • 0344668685 scopus 로고    scopus 로고
    • Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma
    • Sawada M., Tsuda H., Kimura M., Okamoto S., Kita T., Kasamatsu T. et al.: "Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma". Cancer Sci 2003, 94, 986.
    • (2003) Cancer Sci , vol.94 , pp. 986
    • Sawada, M.1    Tsuda, H.2    Kimura, M.3    Okamoto, S.4    Kita, T.5    Kasamatsu, T.6
  • 18
    • 10044268553 scopus 로고    scopus 로고
    • COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: Prognostic factors or potential markers for targeted therapies?
    • Raspollini M.R., Susini T., Amunni G., Paglierani Taddai A., Marchionni M., Scarselli G., Taddei G.L.: "COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?". Gynecol. Oncol., 2005, 96, 159.
    • (2005) Gynecol. Oncol , vol.96 , pp. 159
    • Raspollini, M.R.1    Susini, T.2    Amunni, G.3    Paglierani Taddai, A.4    Marchionni, M.5    Scarselli, G.6    Taddei, G.L.7
  • 21
    • 0141757485 scopus 로고    scopus 로고
    • Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT
    • Rushing R.S., Shajahan S., Chendil D. et al.: "Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT". Gynecol. Oncol., 2003, 91, 9.
    • (2003) Gynecol. Oncol , vol.91 , pp. 9
    • Rushing, R.S.1    Shajahan, S.2    Chendil, D.3
  • 22
    • 1242318769 scopus 로고    scopus 로고
    • rd, Alvarez R.D., Partridge E.E., Huh W.K.: Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J. Reprod. Med., 2004, 49, 71.
    • rd, Alvarez R.D., Partridge E.E., Huh W.K.: " Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series". J. Reprod. Med., 2004, 49, 71.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.